Sofamor ends lagreement with ANS (Advanced Neuromodulation Systems):
This article was originally published in Clinica
Sofamor Danek and Advanced Neuromodulation Systems (ANS) have ended their agreement under which ANS was to develop and manufacture products and systems for Sofamor for use in deep brain stimulation. The agreement, which dates back to June, is being terminated owing to the acquisition of Sofamor by Medtronic. Sofamor will accelerate the $8 million payments due to ANS, which will release Sofamor from its commitments. Dallas-based ANS says it will continue to look for other partners for its electrical stimulation technology, which is used to relieve the effects of neurological disorders, such as Parkinson's disease.
You may also be interested in...
Increased fines and penalties are on the cards for manufacturing facilities that fail to comply with proposed new requirements.
The biopharma sector is often accused of a being a slow-moving engine, but a look back over the last 20 years reveals that a lot has changed. In Vivo explores the history of high-impact M&A transactions in the industry between 1999 and 2019.
The Belgian authorities are taking steps to reduce the consumption of benzodiazepine-containing medicines, and have also reiterated the risks associated with the increasing use of opioid medications.